- Home
- SXTP vs PRFX Comparison
SXTP vs PRFX Comparison
Compare SXTP & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | PRFX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.7M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SXTP | PRFX |
|---|---|---|
| Price | $3.95 | $3.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.60 | N/A |
| AVG Volume (30 Days) | ★ 10.5M | 958.4K |
| Earning Date | 03-27-2026 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,364,945.00 | N/A |
| Revenue This Year | $146.28 | N/A |
| Revenue Next Year | $24.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 202.10 | N/A |
| 52 Week Low | $1.36 | $2.73 |
| 52 Week High | $17.68 | $27.35 |
Technical Indicators
Market Signals| Indicator | SXTP | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 87.26 |
| Support Level | $3.56 | $0.58 |
| Resistance Level | $4.44 | $3.60 |
| Average True Range (ATR) | 0.66 | 0.24 |
| MACD | -0.10 | 0.28 |
| Stochastic Oscillator | 28.57 | 80.50 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.